HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt’s Lymphoma Cells by Impeding the Cell Cycle

Abstract

Histone deacetylases (HDACs) inhibitors are novel in cancer therapy nowadays. HDAC6-selective inhibitors exert advantageous effects due to higher selectivity and less toxicity. We explored the anti-tumor effect and the molecular mechanism of cay10603, a potent HDAC6 inhibitor in Burkitt’s lymphoma cells. Our study revealed cay10603 inhibited the proliferation of Burkitt’s lymphoma cell lines, and induced caspase-dependent apoptosis. Cay10603 inhibited the expression of CDKs and cyclins to impede cell cycle progression in both Burkitt’s lymphoma cell lines. Cay10603 also showed the additive effect with vp16 notably. Our data presented the promising anti-tumor effect of cay10603 in the Burkitt’s lymphoma therapy.

Keywords

Burkitt’s lymphoma / HDAC6 / cell cycle / apoptosis

References

[1] JacobsonC, LaCasceA. How I treat Burkitt lymphoma in adults. Blood, 2014, 124(19): 2913-20

[2] CairoMS, SpostoR, GerrardM, et al.. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol, 2012, 30(4): 387-393

[3] MilesRR, ArnoldS, CairoMS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol, 2012, 156(6): 730-743

[4] FalkenbergKJ, JohnstoneRW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov, 2014, 13(9): 673-691

[5] WestAC, JohnstoneRW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest, 2014, 124(1): 30-39

[6] ImaiY, MaruY, TanakaJ. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies. Cancer Sci, 2016, 107(11): 1543-1549

[7] Int J Mol Sci, 2017, 18(5):

[8] BamoduOA, KuoKT, YuanLP, et al.. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Exp Cell Res, 2018, 370(2): 519-530

[9] PinazzaM, GhisiM, MinuzzoS, et al.. Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells. Oncogene, 2018, 37(28): 3839-3851

[10] CeccacciE, MinucciS. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. Br J Cancer, 2016, 114(6): 605-611

[11] Int J Mol Sci, 2018, 19(8):

[12] MarquardL, PoulsenCB, GjerdrumLM, et al.. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology, 2009, 54(6): 688-698

[13] OzakiT, WuD, SugimotoH, et al.. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis, 2013, 4: e610

[14] LiT, ZhangC, HassanS, et al.. Histone deacetylase 6 in cancer. J Hematol Oncol, 2018, 11(1): 111

[15] ZhangZ, CaoY, ZhaoW, et al.. HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma. Cancer Biomark, 2017, 19(2): 169-175

[16] WangZ, HuP, TangF, et al.. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma. Cancer Lett, 2016, 379(1): 134-142

[17] KozikowskiAP, TapadarS, LuchiniDN, et al.. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem, 2008, 51(15): 4370-4373

[18] WangZ, TangF, HuP, et al.. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep, 2016, 36(1): 589-597

[19] DimopoulosMA, GoldschmidtH, NiesvizkyR, et al.. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol, 2017, 18(10): 1327-1337

[20] KaufmanJL, MinaR, JakubowiakAJ, et al.. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J, 2019, 9(1): 3

[21] LafargaV, AymerichI, TapiaO, et al.. A novel GRK2/HDAC6 interaction modulates cell spreading and motility. EMBO J, 2012, 31(4): 856-869

[22] DeakinNO, TurnerCE. Paxillin inhibits HDAC6 to regulate microtubule acetylation, Golgi structure, and polarized migration. J Cell Biol, 2014, 206(3): 395-413

[23] LiY, ShinD, KwonSH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J, 2013, 280(3): 775-793

[24] RyuHW, ShinDH, LeeDH, et al.. HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis. Cancer Lett, 2017, 391: 162-171

[25] CosenzaM, CivalleroM, MarcheselliL, et al.. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. Apoptosis, 2017, 22(6): 827-840

[26] Perez-SalviaM, AldabaE, VaraY, et al.. In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. Haematologica, 2018, 103(11): e537-e540

[27] RoweM, KellyGL, BellAI, et al.. Burkitt’s lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol, 2009, 19(6): 377-388

[28] PaschosK, SmithP, AndertonE, et al.. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog, 2009, 5(6): e1000492

[29] DoucetJP, HussainA, Al-RasheedM, et al.. Differences in the expression of apoptotic proteins in Burkitt’s lymphoma cell lines: potential models for screening apoptosis-inducing agents. Leuk Lymphoma, 2004, 45(2): 357-362

[30] BellanC, LazziS, HummelM, et al.. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood, 2005, 106(3): 1031-1036

[31] Cold Spring Harb Perspect Med, 2014, 4(2):

[32] Diaz-MoralliS, Tarrado-CastellarnauM, MirandaA, et al.. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther, 2013, 138(2): 255-271

[33] LimS, KaldisP. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development, 2013, 140(15): 3079-3093

[34] WickstromSA, MasoumiKC, KhochbinS, et al.. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J, 2010, 29(1): 131-144

[35] RoskoskiRJr.. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacol Res, 2018, 139: 471-488

[36] PaiJT, HsuCY, HuaKT, et al.. NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells. Molecules, 2015, 20(5): 8000-8019

[37] KangR, KroemerG, TangD. The Tumor Suppressor Protein p53 and the Ferroptosis Network. Free Radic Biol Med, 2018

[38] GaidanoG, BalleriniP, GongJZ, et al.. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 1991, 88(12): 5413-5417

[39] DaiC, GuW. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med, 2010, 16(11): 528-536

[40] DyshlovoySA, RastS, HauschildJ, et al.. Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells. Leuk Lymphoma, 2017, 58(12): 2905-2915

[41] Int J Mol Sci, 2018, 19(12):